论文部分内容阅读
目的 探讨Ⅲ期多发性骨髓瘤更有效的治疗方案及延长生存期的方法。方法 按照Durie和Salmon的诊断标准将 3 4例患者分为两组 ,第 1组 18例 ,采用M2 和VAD方案连续交替联合化疗 ;第 2组 16例 ,在联合化疗的基础上 ,加用α 干扰素 ,每次 3 0 0万 μ ,每周 3次 ,总疗程 3～ 9个月。 结果 第 1组 ,完全缓解率 (CR ) 16.7% ,部分缓解率(PR) 2 7.8% ,总有效率 44 .5 % ,平均维持缓解时间 18.2个月 ;第 2组CR 18.8% ,PR 3 1.3 % ,总有效率 5 0 .1% ,平均缓解维持时间 3 3 .5个月。统计学处理 ,有效率两种方案无显著差异 ,但维持缓解时间差异显著。结论 α 干扰素联合化疗治疗Ⅲ期多发性骨髓瘤优于单纯化疗 ,并且可以延长生存期 ,减少化疗的频率 ,延长化疗的间歇期 ,提高生存的质量
Objective To explore more effective treatment options for stage Ⅲ multiple myeloma and to extend the survival period. Methods According to the diagnostic criteria of Durie and Salmon, 34 patients were divided into two groups. Group 1 consisted of 18 patients with continuous alternation of chemotherapy with M2 and VAD regimens. In group 2, 16 patients were treated with combined chemotherapy with α Interferon, 3 million each time, 3 times a week, the total course of treatment of 3 to 9 months. Results In group 1, the complete remission rate (CR) was 16.7%, the partial remission rate (PR) was 7.8%, the total effective rate was 44.5%, and the mean maintenance response time was 18.2 months. In group 2 CR 18.8% and PR 3 1.3 %, The total efficiency of 50.1%, the average remission maintenance time of 33.5 months. Statistical analysis, there is no significant difference between the two programs of effective, but significant differences in the maintenance of remission time. Conclusions Alpha interferon combined with chemotherapy is superior to chemotherapy alone in stage III multiple myeloma, and can prolong survival, reduce the frequency of chemotherapy, prolong the intermittent period of chemotherapy, and improve the quality of life